[A18-82] Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V

Last updated 01.03.2019

Project no.:

Commission awarded on 22.11.2018 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Adult patients with chronic lymphocytic leukaemia who are unsuitable for or have failed treatments with a B-cell receptor pathway inhibitor or chemoimmunotherapy

Result of dossier assessment:

No comparisons with appropriate comparator therapy presented; added benefit neither proven for patients with 17p deletion or TP53 mutation nor for patients without 17p deletion or TP53 mutation


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.